SURVYR

IONS

Ionis Pharmaceuticals, Inc.
$43.96
+$0.54 (1.24%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-42%-27%-12%+4%+19%Oct 2025Oct 2026Apr 202652w high $86.7452w low $42.08
IONSSPY
Wall St. Highest PT $105.00 (+138.9%) Wall St. Avg PT $84.13 (+91.4%)
$42$68$93$118$144POC $75Hi $105Avg $84
Underwater Drawdown %Max DD -51.0%Current -49.2%
0.0%-51.0%
Relative Strength vs SPY-53.3% vs SPYUnderperforming
+65%0%-65%
1W
−$1.44 (3.17%)
1M
−$0.54 (1.21%)
3M
−$11.34 (20.51%)
6M
−$27.82 (38.76%)
YTD
−$35.15 (44.43%)
1Y
−$29.03 (39.77%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
25 analysts · mean score 1.68
1 = Strong Buy · 5 = Sell
Strong Buy936%
Buy1248%
Hold416%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$43.96
Average target$84.13
+$40.17 (+91.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$58.00
Median$85.00
High$105.00
12-month Wall Street target range
Recent analyst rating changes · 30
Upgrade
2026-10-22 · BMO Capital upgraded IONS from Market Perform to Outperform
Upgrade
2026-10-15 · UBS upgraded IONS from Neutral to Buy
Reiterated
2026-09-24 · HC Wainwright & Co. reiterated Buy on IONS
Reiterated
2026-09-22 · JP Morgan reiterated Overweight on IONS
Reiterated
2026-09-15 · Guggenheim reiterated Buy on IONS
Reiterated
2026-09-09 · Barclays reiterated Overweight on IONS
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$7.1B
P/E (next 12 months, estimated)-37.5
52-week range$42.08 – $86.74
Revenue growth (latest quarter vs a year ago)-40.7%
Dividend yieldNo dividend
Analyst consensusBuy (23)
Average analyst price target$84.13 (+91%)

What they do

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for IONS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

IONS earningsNext report in 7 days
Next report · quarter Sep 2026
Wed Nov 4, 2026Before the open
EPS consensus-$0.93 range -$1.08–-$0.65
Revenue consensus$184.4M 20 analysts
Last 4 quarters · EPS vs estimate
Jul 29, 2026-$0.42est -$0.88+51.7%Above estimates
Apr 29, 2026-$0.30est -$0.77+60.9%Above estimates
Feb 25, 2026-$1.15est -$1.22+5.6%Above estimates
Oct 29, 2025-$0.61est -$1.05+41.8%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-25 11:59:37 ET
24-1125-0225-0425-0725-1026-0226-0426-07-1.220.85
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$267.9M-40.7%
2026-03-31$246.1M–
2025-12-31$203.3M–
2025-09-30$156.7M–
2025-06-30$452.0M–

News & catalysts

More news
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Business Wire · Oct 23
Ionis ranked #1 on Science’s Top Employers list
Business Wire · Oct 22
Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment
Stocktwits · Oct 22
Netflix downgraded, Tesla upgraded: Wall Street's top analyst calls
The Fly · Oct 22
BMO Capital Upgrades Ionis Pharmaceuticals to Outperform From Market Perform
MT Newswires · Oct 22
Rating changes
Upgrade
2026-10-22 · BMO Capital upgraded IONS from Market Perform to Outperform
Upgrade
2026-10-15 · UBS upgraded IONS from Neutral to Buy
Reiterated
2026-09-24 · HC Wainwright & Co. reiterated Buy on IONS
Reiterated
2026-09-22 · JP Morgan reiterated Overweight on IONS
Reiterated
2026-09-15 · Guggenheim reiterated Buy on IONS
Reiterated
2026-09-09 · Barclays reiterated Overweight on IONS

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Swayze Eric
EVP Research · 2026-10-16
Sell
$2.3K
Devers Shannon L.
EVP, Chief Human Resources Ofc · 2026-10-16
Sell
$59.1K
Hayden Michael R
Director · 2026-07-31
Buy
$258.0K
Hayden Michael R
Director · 2026-07-30
Buy
$800.7K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-25 11:59:37 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026